From In Silco to In Vivo – Modeling and Simulation Technologies, a Tool for Optimized Drug Development - Joseph Fleishaker, Pfizer Inc.
Absence of Xeno-rejection and Xenoantibody Production in IL-7 KO Recipients After Xenoheart, but not after Xenoskin Transplantation. Shengqiao Li, Yuan.
Shengqiao Li, Yuan Lin, Yehong Yan, Omer Rutgeerts, Caroline Lenaerts, An D Billiau, Mark Waer
